Phenoxymethylpenicillin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Phenoxymethylpenicillin: From Streptococcal Infections to Epiglottitis
One-Sentence Summary
Phenoxymethylpenicillin (Penicillin V) is a narrow-spectrum, oral β-lactam antibiotic conventionally used against Streptococcus species infections. The TxGNN model predicts potential efficacy for Epiglottitis (score 99.90%), but this prediction is currently supported by zero clinical trials and zero published literature — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no NZ license/label text available); known pharmacologically as a narrow-spectrum agent for streptococcal infections |
| Predicted New Indication | Epiglottitis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action data is flagged as a data gap in this evidence pack. Based on the mechanistic notes accompanying the prediction, phenoxymethylpenicillin is a narrow-spectrum, orally administered penicillin that inhibits bacterial cell wall synthesis via penicillin-binding protein (PBP) binding, with activity primarily limited to Streptococcus species.
This mechanism does not align well with epiglottitis. Epiglottitis is most commonly caused by Haemophilus influenzae type b, an organism that frequently produces β-lactamase and is therefore often resistant to penicillin. Epiglottitis is also a respiratory emergency requiring immediate intravenous, broad-spectrum antibiotic coverage (e.g., ceftriaxone) — not an orally administered agent with slow, variable absorption like penicillin V.
The evidence pack's own assessment concludes that the high TxGNN score most likely reflects a superficial "both are respiratory tract infections" association rather than a genuine mechanistic or clinical fit. No clinical trials or literature currently exist to support this specific application.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Phenoxymethylpenicillin currently holds no market authorization in New Zealand (0 licenses on record; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The epiglottitis prediction is evidence level L5 — a model score only, with no supporting clinical trials or literature, and the mechanistic/pharmacokinetic rationale provided is unfavorable (antibacterial spectrum mismatch, oral route unsuitable for an airway emergency). Notably, a secondary TxGNN-predicted indication for this drug — laryngitis (score 99.85%) — does have direct clinical evidence, but that evidence (a double-blind RCT, PMID 3918495, and multiple Cochrane systematic reviews including PMID 26002823) consistently found phenoxymethylpenicillin ineffective, reinforcing caution around broad respiratory-infection repurposing signals for this drug.
To proceed, the following is needed:
- TFDA/NZ package insert warnings and contraindications (currently blocking data gap)
- Verified mechanism-of-action documentation from DrugBank
- Direct clinical or preclinical evidence specific to epiglottitis (currently none identified)
- A regulatory pathway assessment, given the drug is not currently marketed in New Zealand (0 authorizations)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.